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Mycobacterium tuberculosis FabH initiates type II
fatty acid synthase-catalyzed formation of the long
chain (C16–C22) acyl-coenzyme A (CoA) precursors
of mycolic acids, which are major constituents of
the bacterial cell envelope. Crystal structures of
M. tuberculosis FabH (mtFabH) show the substrate
binding site to be a buried, extended L-shaped chan-
nel with only a single solvent access portal. Entrance
of an acyl-CoA substrate through the solvent portal
would require energetically unfavorable reptational
threading of the substrate to its reactive position. Us-
ing a class of FabH inhibitors, we have tested an al-
ternative hypothesis that FabH exists in an ‘‘open’’
form during substrate binding and product release,
and a ‘‘closed’’ form in which catalysis and interme-
diate steps occur. This hypothesis is supported by
mass spectrometric analysis of the product profile
and crystal structures of complexes of mtFabH with
these inhibitors.
INTRODUCTION
The emergence of multidrug-resistant strains of Mycobacterium
tuberculosis and the synergy of tuberculosis (TB) with AIDS have
made TB one of the deadliest contemporary, infectious dis-
eases, accounting for approximately 2–3 million deaths annually.
The low permeability of the M. tuberculosis membrane (which
plays a role in its intracellular survival) and its resistance to
many chemotherapeutic agents (Jarlier and Nikaido, 1994; Ni-
kaido and Jarlier, 1991) are conferred by the long chain a-al-
kyl-b-hydroxy fatty acids (mycolic acids) that constitute approx-
imately 50% of the weight of the lipid-rich cell envelope of the
bacterium. The frontline antitubercular drug isoniazid targets
InhA, an enzyme required for mycolic acid biosynthesis (Rozwar-
ski et al., 1998; Larsen et al., 2002), and other enzymes in the es-
sential fatty acid biosynthetic pathway are also attractive targets
for new TB-therapeutic agents.
Mycolic acids are formed through the sequential activities of
type I and type II fatty acid synthases (FASs) (Asselineau et al.,402 Chemistry & Biology 15, 402–412, April 2008 ª2008 Elsevier Ltd2002). The type I FAS is a homodimer of a multifunctional
polypeptide that carries all of the catalytic activities for de novo
synthesis of coenzyme A (CoA)-linked C16–C26 long chain fatty
acids. Further elongation to C56 meromycolic acids is proposed
to be carried out by a type II FAS, the multiple catalytic activities
of which are each associated with separate polypeptides that
utilize acyl carrier protein (ACP) as shuttle in the extension cycle.
Mycolic acids are formed through condensation of these mero-
mycolic acids with long chain fatty acids (Portevin et al., 2004;
Takayama et al., 2005).
M. tuberculosis FabH (mtFabH), the initiator enzyme of the
type II FAS, is an important link between the FAS types I and II
(Scarsdale et al., 2001; Choi et al., 2000b). It catalyzes a decar-
boxylative condensation of the long chain (C16–C22) acyl-CoA
products of the type I FAS-catalyzed reaction with malonyl-
ACP. The resulting 3-ketoacyl-ACP product is reduced to an
acyl-ACP (extended by two carbons) through the action of three
enzymes (one of which is InhA) (Figure 1; Sacco et al., 2007a,
2007b; Brown et al., 2007). This acyl-ACP is further elongated
in subsequent steps catalyzed by KasA and KasB (Bhatt et al.,
2007; Sridharan et al., 2007). mtFabH can utilize a wide range
of C12–C22 acyl-CoA substrates (Scarsdale et al., 2001; Choi
et al., 2000b; Brown et al., 2005), which distinguishes it from
FabH in other type II FAS systems that typically utilize C2–C6
substrates (Han et al., 1998; Choi et al., 2000a).
The catalytic cycle of homodimeric mtFabH initiates with bind-
ing of acyl-CoA substrate followed by acylation of the active site
cysteine to form a thioester and dissociation of CoA. The car-
bonyl oxygen of the acylthioester intermediate is stabilized in
an oxyanion hole by main chain NH proton donors Cys112
and Ala306 (see Scarsdale et al., 2001 for mtFabH numbering);
the acyl group lies in a ‘‘closed’’ channel that can accommodate
chains up to C16 in length. Malonyl-ACP then binds in the va-
cated CoA binding site where the malonyl carboxylate is stabi-
lized in an anion binding pocket consisting of His244 and
Asn274. These residues also contribute to catalysis of the ma-
lonyl-ACP decarboxylation to form a carbanion, which reacts
with the acyl group in the thioester to form 3-ketoacyl ACP, the
released product of the reaction.
The crystal structure of the Michaelis complex of lauroyl-CoA
with an inactive Cys112Ala mtFabH mutant (Musayev et al.,
2005) clearly shows substrate bound in an ‘‘L’’-shaped chan-
nel of each monomer (Figure 1), with the active site triadAll rights reserved
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Ligand Trafficking in the M. tuberculosis FabHFigure 1. Structure and Proposed Biological Role of mtFabH
Top panel: FabH as a link between the type I and type II FAS pathways of M. tuberculosis.
Bottom panel: backbone structure of Cys112Ala mtFabH homodimer (gold ribbon) in complex with lauroyl-CoA (space filling: green = carbon; red = oxygen; blue =
nitrogen; yellow = sulfur; magenta = phosphorous) bound in the buried, L-shaped binding site of each monomer of the dimer. Also shown is an expansion of
active site residues (gold stick) with functional atoms (color coded as before) and Cys112 modeled from WT mtFabH structure for the lauroyl-CoA.(Cys112-His244-Asn274) at the junction of the two arms of the L
(Figure 1). CoA occupies the solvent accessible pantetheinate
arm of the L, while the acyl group occupies the distal, dead-
end arm of the L, an extended hydrophobic channel that appears
accessible only through the pantetheinate channel. Binding of
lauroyl-CoA substrate would thus appear to require migration
of the hydrophobic lauroyl chain through the pantetheinate bind-
ing channel and around the bend of the L past the hydrophilic
and charged catalytic residues. Formation of the complex in
this manner would present formidable stereochemical and ener-
getic barriers, and dissociation of long chain b-ketoacyl-ACPChemistry & Biologreaction product from this buried hydrophobic site via a reversal
of this process would appear to be equally unfavorable.
These considerations have led us to hypothesize that native
mtFabH adopts a hitherto unobserved ‘‘open’’ conformation,
which offers an alternate pathway with lower energy barriers
for initial substrate binding and final product release. To test
this hypothesis, we prepared inhibitors with hydrophobic arms
that occupy one or both binding channels, and a reactive group
that targets the active site cysteine. The binding modes of these
inhibitors with the wild-type (WT) mtFabH have been established
by mass spectrometry and X-ray crystallography. These samey 15, 402–412, April 2008 ª2008 Elsevier Ltd All rights reserved 403
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binding channel of which is blocked, reveal that inhibitor binding
and reaction still proceed efficiently, but only with one-armed in-
hibitors that bind exclusively in the acyl channel. These experi-
ments provide strong evidence that mtFabH exists in an open
conformation that accepts ligands directly into the acyl binding
channel without entry to the single solvent portal and passage
through the pantetheinate channel of the closed form of the en-
zyme. These results support a new model for substrate binding,
catalysis, and product release in mtFabH.
RESULTS
Inhibitor Design and Activity
We have recently demonstrated that alkyl-CoA disulfide inhibi-
tors target the active site cysteine of both ecFabH and mtFabH
and that inhibition of these enzymes is specific for short (C2) or
long (C10) alkyl chains respectively, matching their acyl chain
substrate specificities (Alhamadsheh et al., 2007). To investigate
the route for ligand binding and reaction with mtFabH, we syn-
thesized linear inhibitors (Figure 2, compounds 1–3) composed
of two arms linked by an oxycarbonyl-disulfide group, which
can potentially react with the reactive site Cys112 by acylation
or by thiol-disulfide exchange. The arms in the compounds
used here are ethanol and decyl and decanoic acid. Each pair
of arms of a compound is potentially able to simultaneously
bind in the acyl and pantetheinate binding channels of mtFabH.
Preliminary analysis under standard conditions (Alhamadsheh
et al., 2007) revealed comparable levels of inhibition for mtFabH
(IC50 values: 1, 3.8 ± 0.5 mM; 2, 2.4 ± 0.8 mM; 3, 2.7 ± 0.2 mM).
Reaction Products and Crystal Structures
of mtFabH and C112A mtFabH with 1
Electrospray ionization mass spectrometry (ESI-MS) was used
to follow modification of the WT mtFabH with an excess of 1.
Under these conditions, the protein was completely modified
(Figure 2, top panel), the two major species exhibiting mass in-
creases of either 230 or 338 Da. The former of these is consistent
with addition of three 77 Da fragments of A (theoretical increase
in mass of 231 Da) to mtFabH monomer, while the latter is con-
sistent with addition of two 77 Da fragments of A and one 185 Da
fragment of B (theoretical increase in mass of 339). These anal-
yses indicated that all three solvent-accessible cysteines in WT
mtFabH (the active site Cys112, plus Cys23 and Cys154) can re-
act with 1 through disulfide exchange and at least one can react
through acylation.
Crystallization of preformed inhibition complex (Table 1) of WT
mtFabH with 1 showed extra electron density at the two surface
cysteines (Cys23 and Cys154), consistent with disulfide-linked
b-mercaptoethanols, and at the active site Cys112, consistent
with acylation by the long B arm fragment of 1. This crystal struc-
ture corresponds to the more abundant trimodified reaction
product denoted (A+A+B) identified by mass spectroscopy.
The contiguous electron density in both mtFabH subunits ex-
tending from the active site Cys112 into both acyl and pantethei-
nate binding channels (Figure 3A) was interpreted and success-
fully refined as dual, conditional half occupancy of each channel
by fragment B of compound 1, the carbonyl carbon of which
forms a thioester with the active site Cys112 sidechain SH.404 Chemistry & Biology 15, 402–412, April 2008 ª2008 Elsevier LtdThe carbonyl oxygen of the thioester-linked fragment B makes
different hydrogen bonding interactions with the protein in its
alternate orientations in the acyl and pantetheinate channels of
each mtFabH monomer subunit. Furthermore, fragment B in
the acyl (or pantetheinate) channel of one FabH monomer differs
from that of its counterpart in the same channel of the other
monomer of the asymmetric unit dimer. Consequently, there
are four distinct local environments of the carbonyl group in
the asymmetric unit. The carbonyl oxygen of fragment B in
both acyl channels of the dimer makes a hydrogen bond to the
main chain NH of Ala306, but not to the NH of Cys112.
However, in one subunit, this carbonyl oxygen makes a long
Figure 2. ESI-MS Analyses of the Product Abundances for the
Reactions of Disulfide Inhibitors with the mfFabH
Adducts made between compounds 1 (A), 2 (B), and 3 (C) with the WT (blue
bars), Cys112Ala (maroon bars), and Ala246Phe (yellow bars) mtFabH are
shown. Reaction products are grouped in descending order of substitution,
as noted along the x axis. Arrows indicate species for which a crystal structure
was obtained.All rights reserved
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Inhibitorsa Protein
Protein
Concentration
(mM)
Protein:Inhibitor
Molar Ratio Reservoir Solution
Lattice Parameters
Accession No.A (Space Group)
1 Wt 0.21 1:3.5 50 mM Na acetate, pH 4.6, 2.4 M
Na formate
68.03, 88.85, 229.74 (C2221) 2QNZ
1 A246F 0.11 1:4 100 mM Na Hepes, pH 7.5, 1 M
K/Na tartrate
67.70, 88.69, 229.90 (C2221) 2QNY
2 Wt 0.15 1:5 100 mM Na Mes, pH 6.5, 50 mM
NaH2PO4/KH2PO4, 1.8 M NaCl
68.28, 88.98, 230.25 (C2221) 2QNX
3 Wt 0.4 1:2.5 100 mM Na Hepes, pH 7.5, 1 M
K/Na tartrate
68.41, 89.12, 233.29 (C2221) 2QO1
3 A246F 0.21 1:4 100 mM Na citrate, pH 5.6, 10%
isopropanol, 18% PEG-4K
55.30, 93.05, 104.72 (P212121) 2QO0
a See Figure 2.hydrogen bond to the side chain of Ser276, while, in the other
subunit, the Ser276 side chain has alternate conformations, both
of which make favorable (2.6 A˚) hydrogen bonds to the ester, but
not to the carbonyl oxygen, of the ligand in the acyl channel.
These hydrogen bonds to the Ser276 side chain OH may
compensate for the absence of the hydrogen bond to the main
chain NH of Cys112 in the oxyanion hole.
The carbonyl oxygen of fragment B bound in the pantetheinate
channel of one subunit makes a hydrogen bond with the side
chain NH2 of Asn274 (3 A˚) but not to His244, the two residues
that constitute the malonyl anion binding site. In the second sub-
unit, the carbonyl oxygen of fragment B bound in the pantethei-
nate channel makes tenuously long hydrogen bonds (3.3 A˚ and
3.6 A˚, respectively) to these groups in the malonyl anion site,
but makes a favorable hydrogen bond (2.5 A˚) to the side chain
of Ser276 in one of its two alternate conformations.
ESI-MS analyses of the Cys112Ala mutant complex prepared
under the same conditions showed no trimodified species (Fig-
ure 2, top panel). Instead, a predominant dimodified species
(mass increase of 152 Da) was observed, consistent with addi-
tion of two 77 Da fragments of A. Two less abundant species
were also observed (mono- and dimodified), consistent with
the addition of a single B fragment and an A+B, respectively,
that together approximated the unmodified species in abun-
dance (Figure 2, top panel). This decrease in the number of cys-
teine modifications coincident with mutation of the active site
Cys112 indicates that it is this residue in the WT mtFabH that
can undergo modification with either fragment A or B.
Reaction of A246F mtFabH with 1
The alternate occupancy of the acyl and pantetheinate channels
of WT mtFabH by the C10H21OCO (B fragment) groups in the
above structures could be realized by two binding orientations
of 1 prior to reaction with the active site Cys112. The alternate
occupancy might also arise if there were only one binding orien-
tation that permitted reaction with C112, with a subsequent
equilibration of the covalently linked C10H21OCO chain between
the two channels. In either case, migration of the inhibitor into the
pantetheinate channel with passage through the active site res-
idues into the acyl channel presents similar formidable energetic
barriers to those facing the natural acyl-CoA substrate. Thus, weChemistry & Biologconsidered that there may be alternative modes for substrate
and ligand entry to the extended mtFabH binding site.
To test this hypothesis, we created an Ala246Phe mutant
mtFabH, which introduces a large obstructive group into the
pantetheinate channel about 8–9 A˚ out from the active site
Cys112. This Ala246Phe mtFabH mutant had no detectable cat-
alytic activity in an elongation assay with lauroyl-CoA and ma-
lonyl-ACP. Mass spectrometry (Figure 2, top panel) revealed
that an incubation of 1 with this Ala246Phe mutant resulted in
the same trimodification seen with the WT enzyme. Both trimo-
dified species (A+A+A and A+A+B) were observed, with an ap-
parent greater abundance of the latter.
The crystal structure of the unliganded Ala246Phe mutant
showed no significant differences in structure relative to the
WT except for the presence of the bulky phenylalanine, which
clearly blocks access to the active site cysteine via the pante-
theinate channel. Electron density was observed in the acyl
channel that can be fit with a free laurate (not linked to the active
site cysteine). Like other mtFabH structures crystallized in the
absence of ligands, including the WT, the electron density in
the acyl channel that can be fit with a free laurate is probably
taken up during expression and purification of the recombinant
mtFabH.
The cocrystal structure of Ala246Phe mtFabH with 1
(Figure 3B) shows the overall structure of the protein to be virtu-
ally identical to that of the unliganded mutant. The hydrophobic
ligand, modeled as laurate in the acyl binding channel of the un-
liganded Ala246Phe crystal structure, is replaced in the liganded
form by electron density contiguous with Cys112 that can be well
fit by fragment B of 1 in thioester linkage with Cys112 (Figure 3B).
There was no ligand electron density in the blocked pantethei-
nate channel. The carbonyl group of B in the Ala246Phe mtFabH
complex assumes two alternate orientations, one toward the
oxyanion hole and the other toward the malonyl anion binding
site. In one subunit, the carbonyl oxygen makes hydrogen bonds
with optimal stereochemistry to NH of Cys112 and Ala306 in
the oxyanion hole of the acyl binding site. In the other subunit, the
hydrogen bond to NH of C112 is too long to be significant,
and the ligand interactions resemble those seen in the WT com-
plex. In both subunits of the dimer of the Ala246Phe ligand com-
plex, the alternative conformation of the carbonyl oriented
toward the malonyl anion binding site positions the oxygeny 15, 402–412, April 2008 ª2008 Elsevier Ltd All rights reserved 405
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Ligand Trafficking in the M. tuberculosis FabHFigure 3. View of the Product Structure of Compound 1 in the Binding Channels of the WT and Ala246Phe Mutant
(A) Stereo view of the WT mtFabH, showing fragment B of its electron density alternately bound in each of the two arms, the acyl channel and the pantetheinate
channel, of the substrate binding site. The map is 2mFo-DFc contoured at 1s. Subunits of the dimeric mtFabH are indicated by the A and B suffix.
(B) Structure of the Ala246Phe mutant with the pantetheinate channel (gray space filling surface) access to the active site cysteine blocked by a phenylalanine
residue and fragment B (2 conformations) of compound 1 bound in the acyl channel.at long hydrogen bond distance from the His244 and Asn274
proton donors.
The vacant pantetheinate channel in the Ala246Phe mutant
confirms that this channel is blocked by the phenylalanine muta-
tion and indicates that 1 must enter the acyl binding channel by
a path other than the pantetheinate channel. We hypothesize
that this alternative path exists in an open form of the enzyme
in which the extended binding site, consisting of the two chan-
nels, is accessible to ingress of the inhibitor as a result of the lift-
ing of a loop that covers both binding channels (see Discussion
below).406 Chemistry & Biology 15, 402–412, April 2008 ª2008 Elsevier LtdReaction of mtFabH, Cys112Ala mtFabH, and Ala246Phe
mtFabH with 2 and 3
Inhibitor 1 contains only one long hydrophobic arm, which, as
shown above, can occupy either channel of WT mtFabH, or
just the acyl binding channel of the Ala246Phe mutant. To deter-
mine the accessibility to the binding sites of the several FabH
forms, we synthesized 2 and 3 (see Figure 2 for structures),
both with two long arms differing only in the addition of a carbox-
ylate group to the C10 alkane chain. These inhibitors with two hy-
drophobic arms are, in principle, competent to bind both chan-
nels of the active site. In addition to providing potential fullAll rights reserved
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ylate of 2 and 3 was expected to both inhibit the putative transit
of the long chain through the pantetheinate channel and into the
acyl channel, and to direct ligand orientation according to the
Figure 4. Structure of Products of Com-
pounds 2 and 3 with WT and Ala246Phe
mtFabH
(A) Structure of the product of compound 2 with
mtFabH showing fragment A0 in the acyl channel
disulfide linked to Cys112, and fragment B0 in the
pantetheinate channel. Arrows identify the acyl
channel and pantetheinate channel. Subunits of
the dimeric mtFabH are indicated by the A and B
suffix.
(B) Structure of the product of compound 3 with
WT mtFabH showing fragment A00 in the acyl chan-
nel disulfide linked to Cys112 and fragment B00 in
the pantetheinate channel.
(C) Structure of the product complex of compound
3 with Ala246Phe mtFabH showing fragment A00 in
the acyl channel disulfide linked to Cys112. The
surface shape of the empty pantetheinate channel
is shown blocked by Phe246.
relative hydrophobicities of the two inhib-
itor arms and the two arms of the binding
channel.
The reaction of WT mtFabH with 2 (Fig-
ure 2, middle panel) resulted in two trimo-
dified products with mass increases of ei-
ther 617 or 648 Da. The lower mass
increase is consistent with addition of
two 217 Da A0 fragments and one 185
Da B0 fragment, while the higher mass in-
crease is consistent with addition of three
217 Da A0 fragments (an overall increase
in theoretical mass of 619 or 651 Da, re-
spectively) per mtFabH monomer. There
was no detectable unmodified protein.
Reaction of 3 with WT mtFabH gave
predominantly trimodified products ex-
clusively with A00 chain fragment (some
A00 + A00 dimodified species were also
observed).
Crystal structures of the WT enzyme
with 2 and 3 showed that, in both cases,
a disulfide species was formed between
the A0 or A00 fragments and the active
site Cys112 (Figures 4A and 4B). In the
structure of WT mtFabH with 2, the unde-
canoic acid group is, surprisingly, in the
acyl channel and the O-undecylcarbono-
thioate lies in the pantetheinate channel,
detached from the C112-disulfide-linked
undecanoic acid and with its carbonyl ox-
ygen oriented toward the malonyl anion
binding site of His244 and Asn274 (Fig-
ure 4A). Hydrogen bonds in this binding
site are close to optimal in one subunit
(2.72 and 2.74 A˚), but are long in the other subunit (3.34 and
3.45 A˚). The crystal structure of WT mtFabH complexed with 3
(Figure 4B) shows the decyl chain in the acyl channel disulfide
linked to Cys112. The O-carboxyundecylcarbonothioate in theChemistry & Biology 15, 402–412, April 2008 ª2008 Elsevier Ltd All rights reserved 407
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O-undecylcarbonothioate group in the complex with 2, with its
carboxylate at the mouth of the pantetheinate channel and its
carbonyl oriented toward the malonyl anion binding site, but
too far from His244 and Asn274 in both subunits to make hydro-
gen bonds. This latter difference, vis a vis the complex with 2,
may be a consequence of lattice interactions of the carboxylate
that are transmitted to the other end of the chain in the malonyl
anion binding site.
These observations demonstrate that the linkage positions of
the undecanoic acid chain and the decyl chain in 2 and 3 do not
determine the orientation of binding these compounds in the acyl
site of mtFabH. For 2, the binding of the undecanoic acid in the
acyl binding channel is possibly stabilized by the presence of the
Arg2024 side chain at the top of the acyl channel in both subunits
(4–5 A˚ from the carboxylate). In one subunit, there is also a hydro-
gen bond between one of the carboxylate oxygens (inferred to be
in the protonated state) and the amido oxygen of the side chain
of Gln191. The recurrence of disulfide exchange products in both
cases where the inhibitor has two long arms suggests that orien-
tation in binding is determined primarily by the positioning of the
oxycarbonyl-disulfide group in the active site. The crystal struc-
tures show that the carbonyl oxygen of this group is directed to-
ward the malonyl anion binding site, and this may be the principal
determinant of ligand orientation. For a mechanism involving
transit through the pantetheinate into the acyl channel, there is
no obvious basis for discrimination in the orientation of the oxy-
carbonyl-disulfide group. This and the presence of the carboxyl-
ate in the acyl channel argue against a threaded transit of
the ligand into its final reactive position and for a lower energy
pathway of entry.
Reaction of 2 and 3 with the Cys112Ala and Ala246Phe mu-
tants leads to no detectable trimodification of the protein (Fig-
ure 2, middle and bottom panels). For both inhibitors 2 and 3,
a predominant reaction product species was the unmodified mu-
tated proteins. These results contrast with those of the WT FabH,
where there was no unmodified protein and the major species
observed with either inhibitor was the trimodified species. A
striking observation from these ESI-MS studies is that the
Ala246Phe mutant behaves like the Cys112Ala mutant with 2
and 3, but like the WT mtFabH with 1. The presence of the phe-
nylalanine mutation dramatically affects reaction of the active
site cysteine, but only with inhibitors having two hydrophobic
arms.
A cocrystallization study of 3 with the Ala246Phe mutant re-
vealed a complex with the A00 fragment linked by a disulfide to
Cys112 and lying in the acyl channel like the ligand complexes
with WT mtFabH (Figure 4C). Fragment B00, which is observed
in the pantetheinate channel of WT mtFabH, is absent in this
Ala246Phe mutant, and this channel remains blocked by the
phenylalanine mutation (Figure 4C). Thus, while the ESI-MS re-
sults indicate that efficient reaction of the active site cysteine
with 3 is compromised by this mutation, the crystal structure
shows that the reaction occurs. These different results may be
due to differences in conditions of preparation of the samples
used for mass spectrometry and for crystallization. Neverthe-
less, formation of the product complex of 3 with the Ala246Phe
mutant by entry of 3 through the pantetheinate channel, which
is blocked, seems unlikely. The most parsimonious hypothesis408 Chemistry & Biology 15, 402–412, April 2008 ª2008 Elsevier Ltdfor its formation is that 3 binds to an open form of the enzyme
through interaction of its oxycarbonyl-disulfide group at the
malonyl anion binding site; this orients A00 in the acyl channel
for disulfide exchange with Cys112, while B00 extends into sol-
vent from the open form in lieu of binding in the pantetheinate
channel, and dissociates when the thiol-disulfide exchange re-
action occurs.
DISCUSSION
Unresolved Aspects of M. tuberculosis FAS II
Enzyme Mechanisms
The M. tuberculosis type II FAS pathway for synthesis of long
chain (>C54) fatty acid precursors of the mycolic acid component
of the bacterial cell wall (Lu et al., 2004) is a proven target for ex-
isting TB treatments and offers other opportunities for develop-
ment of new treatments. Binding and transfer of long chain
acyl reactants and products almost certainly require enzyme
conformational changes and specific protein-protein interac-
tions, some of which may be vulnerable points for therapeutic
development. In particular, it is not clear how some well-charac-
terized enzymes of this pathway can accommodate substrates
of widely variable acyl chain length and how the protein compo-
nents of the pathway interact.
Characterization and structure determination of individual en-
zymes (Rozwarski et al., 1998; Scarsdale et al., 2001; Sridharan
et al., 2007; Cohen-Gonsaud et al., 2002, 2005) and ACP (Wong
et al., 2002) in this pathway provide evidence that conformational
changes of the proteins play an important role in some individual
steps. For instance, conformational changes on substrate bind-
ing to InhA (FabI) provide an accessible acyl binding crevice to
which a C16 D
2,3-dodecenoic thioester binds in a U-shaped con-
formation (Rozwarski et al., 1998). For the reductive enzyme
3-ketoacyl reductase (MabA), open and closed forms of the en-
zyme have been observed, and docking studies suggest that an
L-shaped binding pocket in the open form can accommodate
substrates up to C16 (Cohen-Gonsaud et al., 2002, 2005); how-
ever, it is unclear how physiological substrates with acyl chains
longer than C16 bind to either InhA or MabA. An acyl binding
region for C10 and C12 substrates in the condensing enzyme
mtKasB has been identified and is U-shaped. While this binding
pocket is larger and more occluded than the corresponding
binding region of the Escherichia coli FabB (which catalyzes
the analogous reaction during palmitate biosynthesis in this mi-
croorganism) (Sridharan et al., 2007), there are no data suggest-
ing how the much longer physiological substrates bind to
mtKasB.
There is less information on protein-protein interactions in the
M. tuberculosis type II FAS, but there is evidence that such inter-
actions are essential for mycobacterial viability (Veyron-Churlet
et al., 2005, 2004). Formation of a type II FAS complex, possibly
with some features resembling those in the type I FAS (Jenni
et al., 2007; Lomakin et al., 2007), is likely required to facilitate
passage of the extremely long chain fatty acid substrates be-
tween enzymes.
To date, there is no information on conformational changes or
protein-protein interactions of mtFabH. The linear acyl binding
pocket appears to be capable of accepting substrates only up
to about C16 in length (Scarsdale et al., 2001), while experimentsAll rights reserved
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(Brown et al., 2005). The crystal structure of mtFabH also raises
the question of how substrate (and product) enter (and leave)
the extended L-shaped binding site consisting of two long,
tandem channels, which are roughly perpendicular to each
other. The distal, buried acyl binding channel in the mtFabH
structure appears accessible only through the pantetheinate
channel, which opens to solvent. However, a binding process
in which lauroyl- or other long-chain acyl-CoA is threaded first
through the pantetheinate channel into the acyl channel seems
implausible.
A Model for Substrate Binding
and Product Release in mtFabH
An alternative to this substrate-threading model is a mechanism
in which mtFabH exists in an open conformational state, where
both the acyl and pantetheinate binding channels are accessible.
To test this hypothesis, we used active site-directed oxycar-
bonyl-disulfide inhibitor ligands flanked on each side by alkyl
or carboxyalkyl chains. Since existing crystal structures of both
liganded and unliganded mtFabH are inferred to be in the closed
conformational state of the enzyme, we combined solution ESI-
MS and crystal structure data to analyze the reaction pathways
and product complexes of these inhibitor ligands with mtFabH.
These results provide evidence that these compounds do not
bind to mtFabH by passage through the pantetheinate channel
into the acyl channel. Inhibitor 1 efficiently enters the acyl chan-
nel of the mtFabH Ala246Phe mutant, blocked in the pantethei-
nate channel, and the carboxylated C10 arm of compound 2
binds in the acyl channel of WT mtFabH despite the inferred en-
ergetic obstacle to migration of a polar group through two hydro-
phobic channels. These data argue strongly for an open form of
mtFabH that binds acyl substrates or inhibitors.
A crystal structure of a disordered ecFabH (Qiu et al., 2001),
and recent kinetic data for inhibition of this enzyme with alkyl-
CoA disulfide inhibitors (Alhamadsheh et al., 2007), support a
model in which the open dimeric enzyme becomes ordered on
binding of an acetyl-CoA substrate or methyl-CoA disulfide in-
hibitor. There is no experimental crystal structure in a disordered
or open form for mtFabH, and a large structural change in the
observed closed crystal structure would be required to provide
direct access to the long hydrophobic acyl channel. Inspection
of the mtFabH structure reveals that the extended binding site
of this enzyme could be exposed for concerted binding of long
chain acyl-CoA substrates through movement of a single poly-
peptide segment (residues 183–209, ecFabH numbering), which
forms most of the top of the acyl channel and part of the top of the
pantetheinate channel in mtFabH (Figure 5A). We note that this
flap includes an insertion sequence in mtFabH relative to ecFabH
that mediates intersubunit interactions in the mtFabH dimer. The
extremities of this polypeptide segment coincide with glycine
residues (181 and 207) that are almost completely conserved
across five FabH sequences. Synchronized hinge motions at
each of these glycines could raise this polypeptide flap to expose
most of the substrate binding site of mtFabH to solvent and to
the binding of substrates and ligands (Figure 5). The proposed
opening of this single flap in mtFabH is distinct from the dis-
ordered state of the unliganded ecFabH crystal structure (Qiu
et al., 2001), in which four noncontiguous but proximal polypep-Chemistry & Biologtide loops that constitute much of the substrate binding site and
dimer interface are not visible in the electron density map.
This proposed open conformation of mtFabH provides an un-
derstanding of how both acyl-CoA substrates and the ligands
1–3 bind and react with the WT enzyme and how 1 reacts with
the Ala246Phe mutant. The proposed open conformation of
the mtFabH also offers a solution to the dilemma of how mtFabH
utilizes substrates longer than palmitoyl-CoA (the maximum per-
mitted chain length suggested by the closed mtFabH structure).
Exposure of the acyl binding channel would allow longer chains
Figure 5. Proposed ‘‘Open’’ and ‘‘Closed’’ Structures of mtFabH
(A) Backbone ribbon model of the dimeric Cys112Ala mtFabH complex with
lauroyl-CoA (color-coded space filling) bound in active sites of both mono-
mers. The putative flap that covers the extended L-shaped binding site is col-
ored gold (front) in the right-hand (gray) monomer and magenta (back) in the
left-hand (blue) monomer subunit.
(B) Surface figure of the same dimer rotated 90 about the horizontal axis
showing the two flap covers (gold) of each of the two binding sites (defined
by lauroyl-CoA color-coded space filling). The flap in the blue left monomer
is in the closed conformation, thereby burying the lauroyl-CoA ligand; the
flap in the gray right monomer is in the open conformation (movement shown
by arrow), opening the lauroyl-CoA binding site to solvent.y 15, 402–412, April 2008 ª2008 Elsevier Ltd All rights reserved 409
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exposed hydrophobic underside of the distal end of the opened
flap in a modified closed conformation of mtFabH that is neces-
sarily slightly different from that observed with lauroyl-CoA
substrate (Musayev et al., 2005). We propose that ordering or
closing of the mtFabH on the substrate or inhibitor is required
for efficient reaction with the active site cysteine, and that this
is why 2 and 3 react poorly with the Ala246Phe mutant. Reaction
of this mutant with 3 results in loss of fragment B00, whose only
plausible position during this reaction is extended outward
from the binding site, since the pantetheinate channel is
blocked.
In this model for acyl-CoA binding to mtFabH, the acyl-CoA re-
actant, in principle, could synchronously bind to both arms of the
exposed substrate binding site. Movement to the closed form,
and reaction with Cys112, would follow. CoA product released
from the mouth of the pantetheinate channel would then com-
plete the first stage of the reaction. In the second stage of the
mtFabH reaction, these different paths for substrate binding
and product release would be reversed: the phosphopante-
theine arm of ACP carrying the malonyl thioester would enter
the mouth of the closed pantetheinate channel after CoA disso-
ciation, and, following decarboxylative condensation of malonyl-
ACP, would transition back to the open form of the enzyme to
permit egress of the hydrophobic 3-ketoacyl ACP product.
This open form could also facilitate transfer of the long, hydro-
phobic acyl chain from the acyl channel binding site of mtFabH
to a putative binding site on ACP. This latter step is supported
by kinetic analyses of the complete mtFabH reaction that indi-
cate an apparent difference in acyl group specificity when using
E. coli versus M. tuberculosis ACP (Brown et al., 2005), and by
the structure of butyryl-ACP in which the acyl group is seques-
tered in a site on the ACP. In addition, we have observed ACP-
dependent changes in substrate specificities of other FabH en-
zymes, and kinetic data for inhibition of ecFabH on binding
a MeSSCoA inhibitor are consistent with conformational transi-
tions on malonyl-ACP binding (Alhamadsheh et al., 2007).
SIGNIFICANCE
The Mycobacterium tuberculosis FabH (mtFabH) is pro-
posed to be an important link between the type I and type
II FAS (fatty acid synthase) responsible for mycolic acid
biosynthesis. This work has demonstrated that large-scale
dynamic motions in mtFabH are required for ligand binding.
The data support a new model for catalysis, in which FabH
exists in an ‘‘open’’ form that permits binding of the long
chain acyl-coenzyme A substrate binding and release of
the corresponding 3-ketoacyl ACP product. Catalysis and
intermediate steps in the process are proposed to occur
in a ‘‘closed’’ form of the mtFabH. These conformational
changes may be critical for binding and dissociation steps
in other enzymes of the FAS pathways, including transfers
between the type I and type II FASII components ofM. tuber-
culosis. Protein-protein interactions in these systems and
the conformational changes of the individual proteins may
offer alternative approaches in developing new therapeutics
that target mycolic acid biosynthesis.410 Chemistry & Biology 15, 402–412, April 2008 ª2008 Elsevier LtdEXPERIMENTAL PROCEDURES
Synthesis of Inhibitors 1–3
Details of compound synthesis are described in the Supplemental Data
available with this article online.
Enzyme Expression and Purification
Expression and purification of the WT mtFabH and Cys112Ala mtFabH have
been described previously (Scarsdale et al., 2001; Musayev et al., 2005).
The open reading frame Rv0533c (encoding the mtFabH) in the expression
vector pET-15b (Scarsdale et al., 2001) was mutated with the Quikchange
XL site-directed mutagenesis kit (Stratagene) to obtain an expression system
for the Ala246Phe mtFabH mutant. Primers used were: 50-GTG TTC GTC CCT
CAT CAG TTC AAT AGC CGC ATC AAC GAG-30 and 50-CTC GTT GAT GCG
GCT ATT GAA CTG ATG AGG GAC GAA CAC-30. The appropriate mutation
in the resulting pSSD1 plasmid was confirmed by sequencing. E. coli
BL21DE3 Codon Plus cells (Novagen) were transformed with pSSD1 and the
mtFabH mutant enzyme expressed and purified under the same conditions
used for WT mtFabH. (Scarsdale et al., 2001; Musayev et al., 2005).
mtFabH Assays
mtFabH assays were carried out as previously described (Brown et al., 2005),
substituting malonyl-CoA for malonyl-ACP.
Identification of Modified mtFabH Species by ESI-MS
WT and mutant mtFabHs in 50 mM sodium phosphate buffer, pH 7.0, 15%
glycerol, were desalted with HPLC-grade water with a Hitrap desalting col-
umn (GE biosciences). An aliquot of enzyme (10–40 mM) and each of the in-
hibitors (1, 2, and 3) were incubated separately (at a 1:10 enzyme:inhibitor ra-
tio) at room temperature for 60 min. Excess inhibitor was removed and the
protein concentrated via sequential use of a desalting gel and a Microcon
concentrator (50 kD cutoff). Protein samples stored at 20C were thawed,
diluted to a concentration of approximately 1 pm/ml with 50% methanol/0.1%
formic acid, and analyzed by a quadrupole time-of-flight mass spectrometer
(TOF/MS) (QSTAR XL; Applied Biosystems/MDS Sciex) equipped with a stan-
dard ion source (MDS Sciex). The instrument was externally calibrated in the
positive ion mode with two fragment ion peaks (m/z 175.1190 and
m/z 1285.5444) from the tandem mass spectrum of Glu-fibrinopeptide
(Sigma). Samples were directly infused into the ion source with a 500 ml
syringe at a flow rate of 5 ml/min. The following parameter settings were
used to acquire mass spectra from m/z 600–1600 in the positive ion TOF/
MS mode: spray voltage, 5500 V; GS1 gas, 15 l/hr; declustering potential
(DP), 85 V; DP2, 15 V; focusing potential, 265 V; accumulation time, 1 s. Typ-
ically, spectra were averaged over 120 scans, and the series of multiply
charged ion peaks were deconvoluted by the Bayesian protein reconstruct
tool (in the Bioanalyst QS 1.1 software package) to determine the zero charge
masses of the intact proteins. For all mass calculations, 0.01% mass accu-
racy was set as tolerance limit (<4 Da for mtFabH, the monomeric molecular
of which weight is 37,000).
Treatment of mtFabH with inhibitors 1–3 resulted in appearance of multiple
novel species along with their sodium adducts (up to four sodium adducts
were readily seen). The region of the most abundant species was identified,
and all peaks with areas at least 10% of the most intense peak (species)
were used for calculations. The mass value (36,903 Da) of untreated mtFabH
control was subtracted from each mass value obtained, and the positive
mass difference used to identify the species present. The relative areas of
each peak (taking into account the various sodium adducts for each) were
used to calculate the relative abundance of the species.
Crystallization, X-Ray Data Collection,
and Structure Determination
Crystals were obtained by the hanging-drop vapor diffusion method with 4 ml
drops consisting of a 1:1 ratio of protein:reservoir solution equilibrated against
600 ml of reservoir solution at room temperature. Protein concentration varied
from 4 to 15 mg/ml in 100 mM sodium phosphate buffer, pH 7.0. Inhibitor mol-
ecules were dissolved in methanol to a final concentration of 34 mM (1), 25 mM
(2), and 23 mM (3), and mixed with protein solution at the molar ratios shown
in Table 1. Before crystallization, protein-inhibitor complex mixture wasAll rights reserved
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Ligand Trafficking in the M. tuberculosis FabHTable 2. Data Collection and Refinement Statistic for mtFabH Crystal Structures
Statistics
Accession No.
2QNZ 2QNY 2QNX 2QO1 2QO0
Data Collection
Resolution (A˚) 48.382.30
(2.382.30)a
39.282.15
(2.232.15)
29.062.70
(2.802.70)
39.732.60
(2.692.60)
38.021.85
(1.921.85)
Unique reflections 31,228 (2987) 35,143 (2605) 19,219 (1913) 20,938 (2193) 46884 (4610)
Redundancy 12.43 (7.98) 3.17 (1.95) 3.65 (3.69) 2.54 (2.84) 6.37 (6.17)
Rmerge
b 0.089 (0.206) 0.075 (0.150) 0.120 (0.264) 0.108 (0.244) 0.095 (0.314)
Completeness (%) 99.3 (96.7) 92.2 (69.6) 97.3 (98.0) 93.2 (98.8) 99.8 (99.9)
I/s (I) 19.6 (9.5) 10.7 (4.4) 8.7 (4.8) 7.4 (4.1) 11.3 (5.5)
Refinement
Resolution (A˚) 14.812.30
(2.382.30)
10.002.15
(2.202.15)
15.002.70
(2.772.70)
15.002.60
(2.672.60)
25.001.85
(1.901.85)
No. of reflections (work) 27,984 (1943) 31,289 (1625) 17,172 (1209) 18,707 (1459) 42064 (3050)
No. of reflections (test) 3115 (207) 3445 (182) 1954 (147) 2076 (146) 4710 (368)
Rwork/Rfree
c 0.164/0.222
(0.192/0.257)
0.195/0.245
(0.215/0.273)
0.209/0.254
(0.294/0.347)
0.221/0.298
(0.287/0.358)
0.194/0.264
(0.314/0.371)
Average B (A˚2) 28.9 30.2 26.8 40.5 22.9
DPI (A˚)d 0.212 0.213 0.352 0.389 0.162
Deviations from ideality
Bond lengths (A˚) 0.007 0.007 0.007 0.007 0.009
Bond angles (deg) 1.11 1.08 1.11 1.1 1.22
Ramachandran plot (%)
Most favored 90.7 90.1 88.1 88.8 90.5
Additional allowed 9.0 9.1 11.3 10.4 9.0
Generously allowed 0.2 0.4 0.4 0.5 0.4
Forbidden 0.2 0.4 0.2 0.4 0.2
a Values in parentheses are for highest resolution shell.
b Rmerge =
P jIh  <I>j/<I>, where Ih refers to the measured intensity for a given reflection and <I> refers to the average measured intensity for that
reflection.
c Rwork =
P jFobs  Fcalcj/
P
Fobs, where Fobs and Fcalc refer to the observed and calculated structure factors, respectively.
d DPI = (Natoms/Nobs)
1/2c1/3dminRfree, where Natoms is the number of atoms in the refinement, Nobs is the number of reflections, c is the data set
completeness expressed as a fraction, dmin is the resolution and Rfree is the free R factor.incubated on ice for 2 hr. Crystallization conditions and lattice parameters for
the structures determined are summarized in Table 1.
For X-ray data collection, crystals were cryoprotected in their mother liquid
solution supplemented with 25%–30% glycerol, and, where appropriate, in-
hibitors, before flash cooling in a liquid nitrogen stream. X-ray data were col-
lected at 100K with a Molecular Structure Corporation (MSC) X-Stream
Cryogenic Crystal Cooler System and an R-Axis IV++ image plate detector
with a Rigaku MicroMax-007 X-ray source equipped with MSC Varimax con-
focal optics operating at 40 kV and 20 mA. Data were processed and scaled
with D*Trek (Pflugrath, 1999). Structures were determined via molecular re-
placement with AMORE (Navaza, 1994), with PDB entry 1HZP (Scarsdale
et al., 2001) as a search model, and refined via alternating cycles of manual
fitting into SigmaA weighted 2mfodfc maps in COOT (Emsley and Cowtan,
2004) and computational refinement in CNS (Brunger et al., 1998) and Re-
fmac5 (Murshudov et al., 1999). Ligand topology and parameter files used
in refinement were generated with the PRODRG server (Schuettelkopf and
van Aalten, 2004). Data collection and refinement statistics are summarized
in Table 2.
ACCESSION NUMBERS
Structures have been deposited to the RCSB under ID codes 2QNZ, 2QNY,
2QNX, 2QO1, and 2QO0.Chemistry & BiologSUPPLEMENTAL DATA
Supplemental Data, including Supplemental Experimental Procedures used in
this work, are available online at http://www.chembiol.com/cgi/content/full/
15/4/402/DC1/.
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